ViewPoint Therapeutics attracts $35 mln Series B

San Francisco-based ViewPoint Therapeutics Inc, a developer of crystallin stabilizers to prevent and treat cataracts and presbyopia, has raised $35 million in Series B financing. The Rise Fund led the round with participation from other investors that included Novo Holdings A/S, Biotechnology Value Fund LP, Mission Bay Capital LLC, Lagunita BioSciences LLC and the University of Michigan through its MINTS initiative.

Source: Press Release